Company Overview and News

 
VCR / Vanguard Consumer Discretionary ETF COMMUNICATION SERVICES IDX FUND - 102018

2018-10-12 sec.gov
merged.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form N-1A VCR

51
Should You Invest in the Fidelity MSCI Consumer Discretionary Index ETF (FDIS)?

2018-10-11 zacks
Launched on 10/21/2013, the Fidelity MSCI Consumer Discretionary Index ETF (FDIS - Free Report) is a passively managed exchange traded fund designed to provide a broad exposure to the Consumer Discretionary - Broad segment of the equity market.
HD AMZN FSTA VCR FDIS DIS

 
VCR / Vanguard Consumer Discretionary ETF ESG FUNDS XBRL

2018-10-09 sec.gov
worldfundxbrl_102018.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form N-1A
VCR

 
ETFs to Bet on the Upcoming Holiday Season

2018-10-05 zacks
The National Retail Federation (NRF), the largest retail group in the United States, estimates holiday season sales in the range of $717.45-$720.89 billion, excluding automobile, gasoline and restaurants. This indicates a rise of 4.3%-4.8% from the last holiday season. These numbers are buoyed by a strongly performing economy. The average increase over the past five-years has been 3.9% (see: all the Consumer Discretionary ETFs here).
HD FXD VCR FDIS XRT

30
Big Tech Sector Shake-Up Put These Stocks and ETFs in Focus

2018-09-24 zacks
The biggest change in Wall Street's broad sectors since 1999 is scheduled for today, with a reshuffle of the technology and media sectors. Last year, S&P Dow Jones and MSCI had announced major changes in the Global Industry Classification Standard (GICS) that broadened the old telecommunication sector and renamed it to communication services sector, effective Sep 24, 2018. The shift will reclassify some of the hot and soaring high-growth tech and media stocks, with telecom stocks into a newly-minted communication services sector.
GJV STT EA ABX NWSA PYPL ATVI V NWS VCR TRI CSCO CSCOI DIS ABX

10
Amazon And XLY: Time To Move On

2018-09-24 seekingalpha
Investors who ignore the Global Industry Classification Standard (GICS) risk could be missing out, but a bigger risk is too much of a good thing.
BRK.A STT FTRPR RTH VCR FTR

44
Should You Invest in the First Trust Consumer Discretionary AlphaDEX Fund (FXD)?

2018-09-24 zacks
Launched on 05/08/2007, the First Trust Consumer Discretionary AlphaDEX Fund (FXD - Free Report) is a passively managed exchange traded fund designed to provide a broad exposure to the Consumer Discretionary - Broad segment of the equity market.
FXD TJX AMZN FSTA FENY VCR FDIS LULU FUTY

 
ETFs to Tap Amazon's Growth and Expansion Story

2018-09-21 zacks
Amazon (AMZN - Free Report) has gained nearly 64% year to date in comparison with the S&P 500, which has gained 8.8%. On Sep 4, it became the second company to reach the trillion-dollar feat after Apple (AAPL) (read: Amazon Hits Trillion Dollar Market Cap: ETFs to Buy). Amazon has miles to go with the recent developments taking place. Plan of Opening 3000 Cashierless Stores by 2021 Amazon is planning to expand its cashierless AmazonGo stores chain to 3000 by 2021.
IYC ONLN RTH VCR FDIS SPG EOG

 
VCR / Vanguard Consumer Discretionary ETF ESG FUNDS 497J COVER LETTER

2018-09-20 sec.gov
attycover_497j.htm - Generated by SEC Publisher for SEC Filing September 20, 2018 U.S. Securities &
VCR

1
FAANG ETFs Face Off Amid New Tariffs: Apple Vs. Amazon

2018-09-19 zacks
The technology sector has witnessed huge sell-off in the first week of September triggered by congressional scrutiny of social media companies that raised fears of a new regulation. This was followed by a decline in chip stocks on warnings over weakness in demand for memory chips. Notably, two of the FAANG stocks — Apple (AAPL - Free Report) and Amazon (AMZN - Free Report) — lost more than $100 billion in market cap combined in the tech rout and dropped below the recently claimed trillion-dollar company.
VGT ONLN IYC IETC IYW VCR AAPL IGM

36
Should You Invest in the Fidelity MSCI Consumer Discretionary Index ETF (FDIS)?

2018-09-19 zacks - 1
Launched on 10/21/2013, the Fidelity MSCI Consumer Discretionary Index ETF (FDIS - Free Report) is a passively managed exchange traded fund designed to provide a broad exposure to the Consumer Discretionary - Broad segment of the equity market.
HD AMZN FSTA CMCSA VCR FDIS

 
VCR / Vanguard Consumer Discretionary ETF ESG INTERNATIONAL STOCK ETF SUMMARY

2018-09-18 sec.gov
sp4394092018.htm - Generated by SEC Publisher for SEC Filing Vanguard ESG International Stock ETF Summary Prospectus
VCR

 
VCR / Vanguard Consumer Discretionary ETF ESG U.S. STOCK ETF SUMMARY

2018-09-18 sec.gov
sp4393092018.htm - Generated by SEC Publisher for SEC Filing Vanguard ESG U.S. Stock ETF Summary Prospectus<
VCR

 
VCR / Vanguard Consumer Discretionary ETF ESG FUNDS 485B FILING

2018-09-18 sec.gov
esgfundsmerge.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form N-1A
VCR

 
VCR / Vanguard Consumer Discretionary ETF WORLD FUND FORM 8-A

2018-09-18 sec.gov
etfform8-aforvanguardesg.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION
VCR

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 92204A504